Alcon Launches Voyager DSLT: Revolutionary Automated Laser Treatment for Glaucoma
Key Insights
Alcon introduces Voyager DSLT (search), the first automated Direct Selective Laser Trabeculoplasty device, offering a groundbreaking first-line treatment option for nearly 5 million Americans with glaucoma (search).
The innovative system delivers 120 laser pulses automatically without requiring a gonio lens, streamlining the treatment process and improving both physician and patient experience.
The commercial launch will be showcased at the 2025 American Glaucoma (search) Society meeting in Washington, D.C., addressing a growing need as U.S. glaucoma cases are projected to reach 6.3 million by 2050.
Alcon (SIX/NYSE: ALC), the global leader in eye care, has announced the full U.S. commercial launch of its groundbreaking Voyager™ DSLT (Direct Selective Laser Trabeculoplasty) system, marking a significant advancement in glaucoma (search) treatment technology. This first-of-its-kind automated laser system represents a major step forward in making laser therapy more accessible as a first-line treatment option for glaucoma and ocular hypertension (search) patients.
Revolutionary Treatment Automation
The Voyager DSLT (search) system distinguishes itself through its fully automated delivery of 120 laser pulses, eliminating the need for a gonio lens traditionally required in manual SLT procedures. This automation not only streamlines the treatment workflow but also enhances the overall treatment experience for both healthcare providers and patients.
Dr. Inder Paul Singh, President of The Eye Centers of Racine and Kenosha (search), who has been utilizing the system since October 2024, shares his experience: "Voyager DSLT (search) has made an incredible impact on the use of SLT for my practice. My patients have been delighted by the efficiency, comfort level of the treatment, and overall experience. The system has been easily implemented by my staff, enabling us to treat more patients with a recognized first-line standard in glaucoma (search) treatment."
Addressing a Growing Healthcare Need
The launch comes at a crucial time as glaucoma (search) continues to pose a significant public health challenge. Current statistics indicate that nearly 5 million Americans are diagnosed with glaucoma, and this number is projected to increase to 6.3 million by 2050. As the leading cause of irreversible blindness globally, glaucoma often progresses silently, with many patients unaware of their condition until vision loss occurs.
Clinical Implementation and Availability
Healthcare professionals will have the opportunity to experience Voyager DSLT (search) firsthand at the upcoming 2025 American Glaucoma (search) Society (AGS) meeting in Washington, D.C., scheduled from February 26 through March 2. Alcon will showcase the technology at their booth (#29-32) and host a dedicated launch event for interested practitioners.
The introduction of Voyager DSLT (search) represents a significant advancement in early intervention strategies for glaucoma (search) management. Its automated approach not only simplifies the treatment process but also has the potential to expand access to laser therapy as a first-line treatment option, potentially improving outcomes for patients who require early intervention to preserve their vision.